AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9745150 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 500 ml at 25 ml/min
Number of subjects: 119
Study 9745150 — intervention group
Group type: COMPARATOR
Intervention: Control group (no infusion)
Number of subjects: 119
Study 7821060 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy (5 fractions of 2 Gy each)
Number of subjects: 137
Study 7821060 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radiation therapy (10 fractions of 2 Gy each)
Number of subjects: 137
Study 7821060 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radiation therapy (5 fractions of 3.5 Gy each)
Number of subjects: 137
Study 7821060 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of NSAID
Number of subjects: 137
Study 7821060 — intervention group
Group type: EXPERIMENTAL
Intervention: High RT dose with short duration (<= 9 days)
Number of subjects: 137
Study 3152586 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 109
Study 3152586 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 109
Study 11403539 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous proton pump inhibitors
Number of subjects: 0
Study 11403539 — intervention group
Group type: COMPARATOR
Intervention: H2-receptor antagonists
Number of subjects: 0
Study 29792242 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided self-help (USH)
Number of subjects: 135
Study 29792242 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychodynamic-interpersonal psychotherapy (GPIP)
Number of subjects: 135
Study 29792242 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 135
Study 30105381 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeSkills intervention
Number of subjects: 190
Study 30105381 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 190
Study 26904982 — intervention group
Group type: EXPERIMENTAL
Intervention: Crush stenting
Number of subjects: 300
Study 26904982 — intervention group
Group type: COMPARATOR
Intervention: Culotte stenting
Number of subjects: 300
Study 25415737 — intervention group
Group type: EXPERIMENTAL
Intervention: Small doxorubicin drug-eluting beads (100-300 µm)
Number of subjects: 94
Study 25415737 — intervention group
Group type: COMPARATOR
Intervention: Large doxorubicin drug-eluting beads (300-500 and 500-700 µm)
Number of subjects: 94
Study 22495030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygium excision with conjunctival autograft plus corneal polishing
Number of subjects: 16
Study 20881754 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine controlled release (CR) 150 mg
Number of subjects: 39
Study 20881754 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine controlled release (CR) 300 mg
Number of subjects: 39
Study 20881754 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine controlled release (CR) 300 mg in diabetic patients with DGE (n = 10)
Number of subjects: 39
Study 17659916 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 10 microg/kg/day for 5 days
Number of subjects: 41
Study 17659916 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 41
Study 15840681 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA microemulsion, steroids, mycophenolate sodium and basiliximab
Number of subjects: 41
Study 11832356 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (IBU; 1,200 mg/day)
Number of subjects: 24
Study 11832356 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (ACET; 4,000 mg/day)
Number of subjects: 24
Study 11832356 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (PLA)
Number of subjects: 24
Study 11832356 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (IBU) and Acetaminophen (ACET)
Number of subjects: 24
Study 10082173 — intervention group
Group type: EXPERIMENTAL
Intervention: Med‐E‐Jet
Number of subjects: 100
Study 10082173 — intervention group
Group type: EXPERIMENTAL
Intervention: Biojector
Number of subjects: 100
Study 10082173 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 100
Study 10082173 — intervention group
Group type: COMPARATOR
Intervention: Needle infiltration
Number of subjects: 100
Study 7772487 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporin (CyA) 500 mg as a swish-and-spit medication for 5 min three times daily for 6 weeks
Number of subjects: 13
Study 7772487 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid oral paste (triamcinolone acetonide) for 6 weeks
Number of subjects: 13
Study 7772487 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA therapy following corticosteroid treatment
Number of subjects: 13
Study 7772487 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for up to 1 year after treatment
Number of subjects: 13
Study 2112184 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-gamma (rIFN gamma) administered by daily 2-hour bolus injection or by continuous infusion for 14 days at dosages ranging from 3 to 3,000 micrograms/m2
Number of subjects: 0
Study 2112184 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-gamma (rIFN gamma)
Number of subjects: 0
Study 100129 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 16
Study 100129 — intervention group
Group type: EXPERIMENTAL
Intervention: BRL10833
Number of subjects: 16
Study 100129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31860566 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal mesh
Number of subjects: 360
Study 31860566 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral colpopexy
Number of subjects: 360
Study 31860566 — intervention group
Group type: COMPARATOR
Intervention: Native tissue transvaginal repair
Number of subjects: 360
Study 31403587 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 96
Study 31403587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 31403587 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 96
Study 27677943 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 27677943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25840904 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain language table
Number of subjects: 343
Study 25840904 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual condition
Number of subjects: 343
Study 25840904 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative condition
Number of subjects: 343
Study 25840904 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate health literacy (REALM-SF)
Number of subjects: 343
Study 25840904 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher income
Number of subjects: 343
Study 25840904 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher subjective numeracy skills
Number of subjects: 343
Study 25840904 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 343
Study 25125716 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 0
Study 25125716 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard doses of testosterone
Number of subjects: 0
Study 21910947 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein-based beverage
Number of subjects: 219
Study 21910947 — intervention group
Group type: COMPARATOR
Intervention: Low-protein high-carbohydrate beverage (control)
Number of subjects: 219
Study 19828019 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated total knee prosthesis
Number of subjects: 120
Study 19828019 — intervention group
Group type: COMPARATOR
Intervention: Uncoated total knee prosthesis
Number of subjects: 120
Study 18182868 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation program (2 sessions, 2 hours daily for 5 days)
Number of subjects: 38
Study 18182868 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 38
Study 15899020 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multipurpose
Number of subjects: 30
Study 15899020 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% ferric oxalate (Sensodyne sealant)
Number of subjects: 30
Study 15899020 — intervention group
Group type: COMPARATOR
Intervention: Acid etching and NaOCl
Number of subjects: 30
Study 15899020 — intervention group
Group type: COMPARATOR
Intervention: Acid etching-sealed dentine
Number of subjects: 30
Study 15899020 — intervention group
Group type: COMPARATOR
Intervention: Scotchbond Multipurpose and Sensodyne sealant
Number of subjects: 30
Study 15311312 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus subgingival minocycline (SM)
Number of subjects: 36
Study 15311312 — intervention group
Group type: COMPARATOR
Intervention: SRP plus vehicle
Number of subjects: 36
Study 11505243 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort touch
Number of subjects: 45
Study 9506749 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose flunisolide (H FN, 2000 microg/day)
Number of subjects: 12
Study 9506749 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose triamcinolone acetonide (H TAA, 1600 microg/day)
Number of subjects: 12
Study 9506749 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose flunisolide (L FN, 1000 microg/day)
Number of subjects: 12
Study 9506749 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose triamcinolone acetonide (L TAA, 800 microg/day)
Number of subjects: 12
Study 9506749 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study 7534320 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (Norditropin, 4 I.U. twice daily) for 6 weeks
Number of subjects: 20
Study 7534320 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment
Number of subjects: 20
Study 7534320 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Number of subjects: 20
Study 7534320 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human growth hormone and Conventional medical treatment
Number of subjects: 20
Study 3076793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg sublingually
Number of subjects: 0
Study 31763933 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First program
Number of subjects: 418
Study 30169980 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin nanostructured lipid carriers (NLCs)
Number of subjects: 0
Study 30169980 — intervention group
Group type: COMPARATOR
Intervention: Melatonin solution
Number of subjects: 0
Study 28369269 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet behavioral weight loss program
Number of subjects: 40
Study 28369269 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 26412528 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated Saccharomyces cerevisiae JCM 7255
Number of subjects: 0
Study 23433639 — intervention group
Group type: EXPERIMENTAL
Intervention: BPRS total score of 18
Number of subjects: 3767
Study 23433639 — intervention group
Group type: EXPERIMENTAL
Intervention: BPRS total score of 30
Number of subjects: 3767
Study 23433639 — intervention group
Group type: EXPERIMENTAL
Intervention: BPRS total score of 40
Number of subjects: 3767
Study 23433639 — intervention group
Group type: EXPERIMENTAL
Intervention: BPRS total score of 50
Number of subjects: 3767
Study 23433639 — intervention group
Group type: EXPERIMENTAL
Intervention: BPRS improvement of 10 points
Number of subjects: 3767
Study 23433639 — intervention group
Group type: EXPERIMENTAL
Intervention: BPRS improvement of 20 points
Number of subjects: 3767
Study 23433639 — intervention group
Group type: EXPERIMENTAL
Intervention: BPRS improvement of 30 points
Number of subjects: 3767
Study 23433639 — intervention group
Group type: EXPERIMENTAL
Intervention: BPRS improvement of 40 points
Number of subjects: 3767
Study 23433639 — intervention group
Group type: EXPERIMENTAL
Intervention: BPRS percentage improvement of 19% from baseline
Number of subjects: 3767
Study 23433639 — intervention group
Group type: EXPERIMENTAL
Intervention: BPRS percentage improvement of 30% from baseline
Number of subjects: 3767
Study 23433639 — intervention group
Group type: EXPERIMENTAL
Intervention: BPRS percentage improvement of 40% from baseline
Number of subjects: 3767
Study 23433639 — intervention group
Group type: EXPERIMENTAL
Intervention: BPRS percentage improvement of 50% from baseline
Number of subjects: 3767
Study 21599894 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary, evidence-based care program for depression management
Number of subjects: 0
Study 21599894 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 21599894 — intervention group
Group type: EXPERIMENTAL
Intervention: Care program
Number of subjects: 0
Study 18343310 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant boost radiotherapy (67.5 Gy/40 fractions over 5 weeks)
Number of subjects: 0
Study 18343310 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (66 Gy in 33 fractions over 6.5 weeks)
Number of subjects: 0
Study 18343310 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant boost radiotherapy
Number of subjects: 0
Study 18343310 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 0
Study 16839840 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion after exercise
Number of subjects: 7
Study 16839840 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion at rest
Number of subjects: 7
Study 16839840 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion in both trials
Number of subjects: 7
Study 12959745 — intervention group
Group type: EXPERIMENTAL
Intervention: Downregulated isoprenoid pathway with decreased digoxin synthesis in patients with left hemispheric dominance.
Number of subjects: 0
Study 12959745 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased lysosomal stability, elevated ubiquinone levels, and decreased free radical levels in patients with left hemispheric dominance.
Number of subjects: 0
Study 12959745 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperdigoxinemia with an upregulated isoprenoid pathway in patients with right hemispheric dominance.
Number of subjects: 0
Study 10689885 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast medium volume of 120 ml
Number of subjects: 48
Study 10689885 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast medium volume of 2.0 <, < or = 2.5 ml/kg
Number of subjects: 48
Study 8936543 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 g standard bevelled intramuscular needle
Number of subjects: 623
Study 8936543 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 g standard bevelled intramuscular needle
Number of subjects: 623
Study 8936543 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 g short bevelled 'regional block' needle
Number of subjects: 623
Study 1593248 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a specific group cessation program (including a video and waived fees)
Number of subjects: 1380
Study 1593248 — intervention group
Group type: COMPARATOR
Intervention: Advice only (control group)
Number of subjects: 1380
Study 3920862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 43
Study 3920862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 30987551 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid (ALA) 600 mg daily for 8 weeks
Number of subjects: 63
Study 30203760 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy combined with radioactive iodine
Number of subjects: 120
Study 30203760 — intervention group
Group type: COMPARATOR
Intervention: Conventional total thyroidectomy
Number of subjects: 120
Study 26802793 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing usual worry with images of possible positive outcomes
Number of subjects: 0
Study 26802793 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing usual worry with positive outcomes represented verbally
Number of subjects: 0
Study 26802793 — intervention group
Group type: COMPARATOR
Intervention: Generating positive images not related to worries (control condition)
Number of subjects: 0
Study 25942341 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cells in combination with bioresorbable PLA/PGA membrane
Number of subjects: 24
Study 25942341 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 24
Study 22067774 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% intrauterine lidocaine infusion
Number of subjects: 58
Study 22067774 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 58
Study 18690013 — intervention group
Group type: EXPERIMENTAL
Intervention: Infanrix hexa (GlaxoSmithKline Biologicals; N = 246)
Number of subjects: 494
Study 18690013 — intervention group
Group type: COMPARATOR
Intervention: Hexavac (Sanofi Pasteur MSD; N = 248)
Number of subjects: 494
Study 18690013 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 494
Study 17167254 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sucrose solution exposure 2 times/day
Number of subjects: 10
Study 17167254 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sucrose solution exposure 4 times/day
Number of subjects: 10
Study 17167254 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sucrose solution exposure 6 times/day
Number of subjects: 10
Study 17167254 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sucrose solution exposure 8 times/day
Number of subjects: 10
Study 17167254 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sucrose solution exposure 10 times/day
Number of subjects: 10
Study 17167254 — intervention group
Group type: COMPARATOR
Intervention: Control (0 times/day sucrose exposure)
Number of subjects: 10
Study 15987395 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid loading with 2 litres of Ringer acetate
Number of subjects: 10
Study 15987395 — intervention group
Group type: COMPARATOR
Intervention: No fluid loading
Number of subjects: 10
Study 15987395 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid loading
Number of subjects: 10
Study 12462684 — intervention group
Group type: EXPERIMENTAL
Intervention: Banded Herbst appliance for six months
Number of subjects: 28
Study 12462684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast-silver splinted Herbst appliances for seven months
Number of subjects: 28
Study 12462684 — intervention group
Group type: COMPARATOR
Intervention: Both appliances
Number of subjects: 28
Study 10075384 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavonoid supplement (55 mg daily including 30 mg genistein, 16 mg biochanin A, 1 mg daidzein, 8 mg formononetin)
Number of subjects: 59
Study 10075384 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 59
Study 10075384 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavonoid supplement
Number of subjects: 59
Study 7719894 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler inhalation of terbutaline (0.125, 0.25, 0.5, 1.0, 2.0 mg doses)
Number of subjects: 31
Study 7719894 — intervention group
Group type: COMPARATOR
Intervention: Pressurized metered dose inhaler inhalation of terbutaline (0.125, 0.25, 0.5, 1.0, 2.0 mg doses)
Number of subjects: 31
Study 7719894 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler and Pressurized metered dose inhaler
Number of subjects: 31
Study 1827311 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiroplatin at 30 mg/m2 by 4 h infusion every 3 weeks (recommended dose for phase II studies)
Number of subjects: 67
Study 1827311 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiroplatin at 35 mg/m2 (MTD for poor-risk patients)
Number of subjects: 67
Study 1827311 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiroplatin at 40 mg/m2 (MTD for good-risk patients)
Number of subjects: 67
Study 1827311 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiroplatin (dose-dependent)
Number of subjects: 67
Study 6976947 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 24
Study 6976947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6976947 — intervention group
Group type: COMPARATOR
Intervention: Coltsfoot
Number of subjects: 24
Study 6705447 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐mg nicotine gum
Number of subjects: 12
Study 6705447 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐mg nicotine gum
Number of subjects: 12
Study 6705447 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 12
Study 31222392 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily symptom reporting with electronic patient-reported outcomes (PROs)
Number of subjects: 76
Study 30322156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care group (moderate hypocaloric Mediterranean diet and nutritional education)
Number of subjects: 107
Study 30322156 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 107
Study 26955912 — intervention group
Group type: EXPERIMENTAL
Intervention: Group physiotherapy (GRP)
Number of subjects: 34
Study 26955912 — intervention group
Group type: COMPARATOR
Intervention: Individual physiotherapy (IND)
Number of subjects: 34
Study 25195060 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (8 mg intravenously before surgery)
Number of subjects: 80
Study 25195060 — intervention group
Group type: COMPARATOR
Intervention: Control (no betamethasone)
Number of subjects: 80
Study 22366106 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ambulation at 4 hours post-cardiac catheterization
Number of subjects: 137
Study 22366106 — intervention group
Group type: COMPARATOR
Intervention: Routine post-procedure care of 12 to 24 hours (Control)
Number of subjects: 137
Study 20615842 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making
Number of subjects: 16
Study 18689565 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 36
Study 18689565 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (SE)
Number of subjects: 36
Study 15926966 — intervention group
Group type: EXPERIMENTAL
Intervention: CRN team leader and CRNs
Number of subjects: 378